Search

Your search keyword '"Delabar, Jean-Maurice"' showing total 334 results
Start Over Author "Delabar, Jean-Maurice"
334 results on '"Delabar, Jean-Maurice"'

1. Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society.

Author

Dierssen, Mara, Herault, Yann, Helguera, Pablo, Martínez de Lagran, Maria, Vazquez, Anna, Christian, Bradley, Carmona-Iragui, Maria, Wiseman, Frances, Mobley, William, Fisher, Elizabeth MC, Brault, Veronique, Esbensen, Anna, Jacola, Lisa M, Potier, Marie Claude, Hamlett, Eric D, Abbeduto, Leonard, Del Hoyo Soriano, Laura, Busciglio, Jorge, Iulita, Maria Florencia, Crispino, John, Malinge, Sébastien, Barone, Eugenio, Perluigi, Marzia, Costanzo, Floriana, Delabar, Jean Maurice, Bartesaghi, Renata, Dekker, Alain D, De Deyn, Peter, Fortea Ormaechea, Juan, Shaw, Patricia A, Haydar, Tarik F, Sherman, Stephanie L, Strydom, André, and Bhattacharyya, Anita

Subjects
Alzheimer's disease, Biomarkers, Down syndrome, Intellectual disability, Language impairment, Mouse models, Neurodevelopmental disorders, Trisomy 21 Research Society, Alzheimer&#8217, s disease, Down Syndrome, Neurosciences, Brain Disorders, Cancer, Intellectual and Developmental Disabilities (IDD), 2.1 Biological and endogenous factors, Genetics, Clinical Sciences
Abstract

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.

Published
2021

2. Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society.

Author

Delabar, Jean-Maurice, Allinquant, Bernadette, Bianchi, Diana, Blumenthal, Tom, Dekker, Alain, Edgin, Jamie, O'Bryan, John, Dierssen, Mara, Potier, Marie-Claude, Wiseman, Frances, Guedj, Faycal, Créau, Nicole, Reeves, Roger, Gardiner, Katheleen, and Busciglio, Jorge

Subjects
Down Syndrome, Trisomy 21 Research Society, Neurodegenerative, Acquired Cognitive Impairment, Neurosciences, Dementia, Alzheimer's Disease, Aging, Intellectual and Developmental Disabilities (IDD), Pediatric, Brain Disorders, Genetics, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Aetiology, 2.1 Biological and endogenous factors, Congenital, Clinical Sciences
Abstract

Down syndrome (DS) is the most common genetic cause of intellectual disability (ID) in humans with an incidence of ∼1:1,000 live births worldwide. It is caused by the presence of an extra copy of all or a segment of the long arm of human chromosome 21 (trisomy 21). People with DS present with a constellation of phenotypic alterations involving most organs and organ systems. ID is present in all people with DS, albeit with variable severity. DS is also the most frequent genetic cause of Alzheimer's disease (AD), and ∼50% of those with DS will develop AD-related dementia. In the last few years, significant progress has been made in understanding the crucial genotype-phenotype relationships in DS, in identifying the alterations in molecular pathways leading to the various clinical conditions present in DS, and in preclinical evaluations of potential therapies to improve the overall health and well-being of individuals with DS. In June 2015, 230 scientists, advocates, patients, and family members met in Paris for the 1st International Conference of the Trisomy 21 Research Society. Here, we report some of the most relevant presentations that took place during the meeting.

Published
2016

3. Translating molecular advances in Down syndrome and Fragile X syndrome into therapies

Author

Antonarakis, Stylianos, Bartesaghi, Renata, Contestabile, Andrea, Coppus, Tonnie, De Deyn, Peter, Dekker, Alain, Delabar, Jean-Maurice, Dierssen, Mara, Fisher, Elisabeth, Hérault, Yann, Martinez-Cué, Carmen, Potier, Marie-Claude, Strydom, Andre, Faundez, Victor, De Toma, Ilario, Bardoni, Barbara, Nizetic, Dean, de la Torre, Rafael, Cohen Kadosh, Roi, and Herault, Yann

Published
2018
Full Text
View/download PDF

8. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial

Author

de la Torre, Rafael, de Sola, Susana, Hernandez, Gimena, Farré, Magí, Pujol, Jesus, Rodriguez, Joan, Espadaler, Josep María, Langohr, Klaus, Cuenca-Royo, Aida, Principe, Alessandro, Xicota, Laura, Janel, Nathalie, Catuara-Solarz, Silvina, Sanchez-Benavides, Gonzalo, Bléhaut, Henri, Dueñas-Espín, Iván, del Hoyo, Laura, Benejam, Bessy, Blanco-Hinojo, Laura, Videla, Sebastiá, Fitó, Montserrat, Delabar, Jean Maurice, and Dierssen, Mara

Published
2016
Full Text
View/download PDF

20. Corrigendum to: DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome

Author

Lepagnol-Bestel, Aude-Marie, primary, Zvara, Agnes, additional, Maussion, Gilles, additional, Quignon, Frédérique, additional, Ngimbous, Bedel, additional, Ramoz, Nicolas, additional, Imbeaud, Sandrine, additional, Loe-Mie, Yann, additional, Benihoud, Karim, additional, Agier, Nicolas, additional, Salin, Paul A, additional, Cardona, Ana, additional, Khung-Savatovsky, Suonavy, additional, Kallunki, Pekka, additional, Delabar, Jean-Maurice, additional, Puskas, Laszlo G, additional, Delacroix, Hervé, additional, Aggerbeck, Lawrence, additional, Delezoide, Anne-Lise, additional, Delattre, Olivier, additional, Gorwood, Philip, additional, Moalic, Jean-Marie, additional, and Simonneau, Michel, additional

Published
2021
Full Text
View/download PDF

30. BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients

Author

Tlili, Asma, Hoischen, Alexander, Ripoll, Clémentine, Benabou, Eva, Badel, Anne, Ronan, Anne, Touraine, Renaud, Grattau, Yann, Stora, Samantha, van Bon, Bregje, de Vries, Bert, Menten, Björn, Bockaert, Nele, Gecz, Joseph, Antonarakis, Stylianos E., Campion, Dominique, Potier, Marie-Claude, Bléhaut, Henri, Delabar, Jean-Maurice, and Janel, Nathalie

Published
2012
Full Text
View/download PDF

42. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome

Author

Lepagnol-Bestel, Aude-Marie, Zvara, Agnes, Maussion, Gilles, Quignon, Frédérique, Ngimbous, Bedel, Ramoz, Nicolas, Imbeaud, Sandrine, Loe-Mie, Yann, Benihoud, Karim, Agier, Nicolas, Salin, Paul A., Cardona, Ana, Khung-Savatovsky, Suonavy, Kallunki, Pekka, Delabar, Jean-Maurice, Puskas, Laszlo G., Delacroix, Hervé, Aggerbeck, Lawrence, Delezoide, Anne-Lise, Delattre, Olivier, Gorwood, Philip, Moalic, Jean-Marie, and Simonneau, Michel

Published
2009

50. DYRK1A Is a Regulator of S-Phase Entry in Hepatic Progenitor Cells

Author

Kruitwagen, Hedwig S., Westendorp, Bart, Viebahn, Cornelia S., Post, Krista, van Wolferen, Monique E., Oosterhoff, Loes A., Egan, David A., Delabar, Jean-Maurice, Toussaint, Mathilda J., Schotanus, Baukje A., de Bruin, Alain, Rothuizen, Jan, Penning, Louis C., Spee, Bart, dCSCA RMSC-1, Onderzoek, LS Pathobiologie, dPB RMSC, LS Interne geneeskunde, LS Algemene chirurgie, Biochemisch laboratorium, and dCSCA AVR

Subjects
proliferation, RNA interference screen, cell cycle, DYRK1A, hepatic progenitor cells
Abstract

Plant cells contain two major pools of K+, one in the vacuole and one in the cytosol. The behavior of K+ concentrations in these pools is fundamental to understand-ing the way this nutrient affects plantigrowth. Triple-barreled microelectrodes have been used to obtain the first fully quantitative measurements of the changes in K+ activity (ay) in the vacuole and cytosol of barley (Hordeum vulgare L.) root cells grown in different K+ concentrations. The electrodes incorporate a pH-selective barrel allowing each measurement to be assigned to either the cytosol or vacuole. The measure-ments revealed that vacuolar aK declined linearly with de-creases in tissue K+ concentration, whereas cytosolic aK initially remained constant in both epidermal and cortical cells but then declined at different rates in each cell type. An unexpected finding was that cytoplasmic pH declined in parallel with cytosolic aK, but acidification of the cytosol with butyrate did not reveal any short-term link between these two parameters. These measurements show the very different responses of the vacuolar and cytosolic K+ pools to changes in K+ availability and also show that cytosolic K+ homeostasis differs quantitatively in different cell types. The data have

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results